Piper Sandler Maintains Overweight on Gamida Cell, Lowers Price Target to $2
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff has maintained an Overweight rating on Gamida Cell (NASDAQ:GMDA) but reduced the price target from $5 to $2.
November 15, 2023 | 3:33 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Piper Sandler has maintained an Overweight rating on Gamida Cell but has lowered the price target from $5 to $2, indicating a potential downside compared to the previous target.
The reduction in price target by Piper Sandler suggests a lower expected future stock price for Gamida Cell, which could lead to a negative short term impact on the stock as investors adjust their expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100